Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hummingbird Bioscience
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Rakuten Medical, Inc.
Dana-Farber Cancer Institute
Akeso
Hospital of Stomatology, Wuhan University
Shanghai Jiao Tong University School of Medicine
Beijing Tongren Hospital